Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Servier
Biotech
Nuvation cancels plans to directly challenge Servier's Voranigo
Nuvation’s plans for its brain-penetrant mIDH1 inhibitor, called safusidenib, had involved a head-to-head study against Voranigo.
James Waldron
Nov 4, 2025 7:10am
Servier supercharges neuro pipeline with $450M deal
Sep 8, 2025 2:30am
Servier hands Ideaya $210M upfront for ex-US rights to PKC asset
Sep 2, 2025 3:02pm
Novartis culls ph. 2 knee pain trial testing anti-ADAMTS-5 asset
Apr 16, 2025 2:55pm
Servier severing forces OPM to make 'drastic choices' to adapt
Apr 4, 2025 9:05am
Servier pays $70M for Black Diamond's deprioritized cancer drug
Mar 19, 2025 7:53am
